Patient-Centered Clinical Research Young Investigator Award Grant

Patient-Centered Clinical Research Young Investigator Award Grant

Status: ACTIVE
Funder: Bladder Cancer Advocacy Network Inc
Amount: Up to US $100,000
Last Updated: January 19, 2026

Summary

The Patient-Centered Clinical Research Young Investigator Award (PCC-YIA) supports early-career scientists conducting innovative research in bladder cancer and upper tract urothelial cancer. This award facilitates studies focusing on patient-centered outcomes, quality of care, and health disparities. Eligible applicants must be within six years of their professional degree and have mentorship from an approved institution. The award promotes transformative research aimed at improving patient experiences and outcomes in clinical settings.

Overview

The Patient-Centered Clinical Research Young Investigator Award (PCC-YIA) supports early-career scientists and clinical cancer researchers investigating transformational patient-oriented clinical bladder cancer and/or upper tract urothelial cancer research (e.g. studies of shared decision making, access to care, quality of care, quality of life, health disparities, comparative effectiveness research, patient-centered outcomes research, and survivorship). Applicants must have a mentor within or approved by the sponsoring institution that will assume responsibility for the overall conduct of the project and provide guidance and protected research time.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website. Applicant must be from a US or Canadian sponsoring academic, non-profit or governmental institution.Applicant must be within 6 years of completion of a professional degree or clinical training and may not hold the title of Associate Professor or higher at the time of submission.

Ineligibility

Prior BCAN Young Investigator Award winners are not eligible to apply for this award.Applicants may not have other funding with significant scientific overlap.Indirect costs are not allowable.